How NMPA Approval of First-in-Class Rabies Antibody Will Impact China Medical System (SEHK:867) Investors

Simply Wall St.06-22

China Medical System Holdings announced that its New Drug Application for Silevimig Injection, a fully human bispecific antibody for passive immunization after rabies exposure, was approved by China’s...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2645748840?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","is_english":true,"pubTime":"2026-06-22 22:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2645748840","market":"us","top_or_hot":-1,"title":"How NMPA Approval of First-in-Class Rabies Antibody Will Impact China Medical System (SEHK:867) Investors","media":"Simply Wall St.","content":"<div>\n<p>China Medical System Holdings announced that its New Drug Application for Silevimig Injection, a fully human bispecific antibody for passive immunization after rabies exposure, was approved by China’s...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-867/china-medical-system-holdings-shares/news/how-nmpa-approval-of-first-in-class-rabies-antibody-will-imp\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>How NMPA Approval of First-in-Class Rabies Antibody Will Impact China Medical System (SEHK:867) Investors</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHow NMPA Approval of First-in-Class Rabies Antibody Will Impact China Medical System (SEHK:867) Investors\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-06-22 22:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-867/china-medical-system-holdings-shares/news/how-nmpa-approval-of-first-in-class-rabies-antibody-will-imp><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>China Medical System Holdings announced that its New Drug Application for Silevimig Injection, a fully human bispecific antibody for passive immunization after rabies exposure, was approved by China’s...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-867/china-medical-system-holdings-shares/news/how-nmpa-approval-of-first-in-class-rabies-antibody-will-imp\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AIPO","symbol_name":"Defiance AI and Power Infrastructure ETF","start_time":0,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-867/china-medical-system-holdings-shares/news/how-nmpa-approval-of-first-in-class-rabies-antibody-will-imp","article_id":"2645748840","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-867/china-medical-system-holdings-shares/news/how-nmpa-approval-of-first-in-class-rabies-antibody-will-imp","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2645748840","pubTimestamp":1782138436,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"China Medical System Holdings announced that its New Drug Application for Silevimig Injection, a fully human bispecific antibody for passive immunization after rabies exposure, was approved by China’s National Medical Products Administration on 22 June 2026, and the company obtained the drug registration certificate.\nThis approval introduces the world’s first dual-epitope rabies bispecific antibody, adding an eighth commercialized innovative drug to the group’s portfolio and enhancing its...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"AIPO":"Defiance AI and Power Infrastructure ETF","IE00BYV24P56.USD":"GUINNESS EMERGING MARKETS EQUITY INCOME \"C\" (USD) ACC","CHAT":"ROUNDHILL GENERATIVE AI & TECHNOLOGY ETF","BK4211":"区域性银行","IE00BMCWC346.EUR":"GUINNESS EMERGING MARKETS EQUITY INCOME \"C\" (EUR) ACC","BK1191":"制药","00867":"康哲药业","BK1593":"医美概念股","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","SG9999015952.SGD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (SGD) ACC","ISBC":"投资者银行","AGIX":"通用人工智能 ETF-AGIX","IE00BVYPNQ40.USD":"GUINNESS ASIAN EQUITY INCOME \"C\" (USD) ACC","SG9999015978.USD":"利安颠覆性创新基金A","IE00BVYPNP33.GBP":"GUINNESS ASIAN EQUITY INCOME \"C\" (GBP) ACC","ARTY":"ISHARES FUTURE AI & TECH ETF","SG9999015945.SGD":"LionGlobal Disruptive Innovation Fund A SGD","IE00BGHQDM52.EUR":"GUINNESS ASIAN EQUITY INCOME \"C\" (EUR) ACC","SG9999004220.SGD":"Nikko AM Shenton Asia Dividend Equity Fund  SGD","SG9999015986.USD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (USD) ACC"},"translate_title":"NMPA批准First-in-Class狂犬病抗体将如何影响康哲药业（SEHK：867）投资者","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ARTY":0.73,"ISBC":1.5,"00867":0.9,"AIPO":0.83,"AGIX":0.73,"CHAT":0.73},"content_text":"China Medical System Holdings announced that its New Drug Application for Silevimig Injection, a fully human bispecific antibody for passive immunization after rabies exposure, was approved by China’s National Medical Products Administration on 22 June 2026, and the company obtained the drug registration certificate. This approval introduces the world’s first dual-epitope rabies bispecific antibody, adding an eighth commercialized innovative drug to the group’s portfolio and enhancing its tiered innovation pipeline. We will now explore how bringing this first-in-class rabies bispecific antibody to market influences China Medical System Holdings’ investment narrative. Explore 31 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.AdvertisementWhat Is China Medical System Holdings' Investment Narrative?For China Medical System Holdings, you really have to believe in its ability to convert a broad, innovation-heavy pipeline into durable, cash-generative products while managing execution risk and capital discipline. The NMPA approval of Silevimig Injection looks material to that story: it adds an eighth innovative drug already on the market, showcases CMS’s biologics capabilities and may slightly rebalance near term catalysts toward commercialization and launch execution, rather than just clinical and regulatory milestones. That said, Silevimig alone probably does not transform the overall risk profile, which still hinges on ramping multiple assets, improving margins from a currently modest 18.1% net margin, and supporting dividends and buybacks when free cash flow cover is thin. The recent share price weakness suggests the market is still cautious about that trade off. However, investors should be aware that dividend support currently leans on constrained free cash flows. Despite retreating, China Medical System Holdings' shares might still be trading above their fair value and there could be some more downside. Discover how much.Exploring Other PerspectivesSEHK:867 1-Year Stock Price Chart Two fair value estimates from the Simply Wall St Community span roughly HK$17.95 to HK$36.20, showing how far apart private investors can be. Set that against CMS’s expanding but execution heavy pipeline, where Silevimig’s approval shifts attention to launch performance and reimbursement, and you can see why it pays to compare several viewpoints before forming your own expectations.Explore 2 other fair value estimates on China Medical System Holdings - why the stock might be worth just HK$17.95!Reach Your Own ConclusionDisagree with this assessment? Extraordinary investment returns rarely come from following the herd, so go with your instincts.A great starting point for your China Medical System Holdings research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.Our free China Medical System Holdings research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate China Medical System Holdings' overall financial health at a glance.Interested In Other Possibilities?Our top stock finds are flying under the radar-for now. Get in early:Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.Outshine the giants: these 14 early-stage AI stocks could fund your retirement.Capitalize on the AI infrastructure supercycle with our selection of the 49 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2645748840","isCrawlerRequest":true}